What is colchicine concentration in Gloriosa superba tubers and seeds?

Colchicine concentrations in Gloriosa superba rhizomes range from 2.12 to 7.58 mg/g dry weight across 32 characterized Indian chemotypes, with the highest-yielding accession (GS-1) reaching 7.58 mg/g. Seeds contain even higher concentrations, ranging from 7 to 9 mg/g (0.7–0.9% dry weight), making them the richest natural source of pharmaceutical-grade colchicine. These concentrations are relevant to industrial extraction, not safe consumption.

Is Gloriosa superba safe to consume or use as a supplement?

Gloriosa superba is not safe for direct consumption or use as a dietary supplement; it is one of the most toxic plants known, with colchicine poisoning causing multistage organ failure including gastrointestinal collapse, cardiac arrhythmia, bone marrow suppression, and death if ingested in sufficient quantity. Even small amounts of raw tuber or seed can deliver doses of colchicine that exceed the narrow therapeutic threshold. No standardized safe supplemental form exists, and all traditional uses carry significant poisoning risk.

What are the traditional medicinal uses of Gloriosa superba?

In Ayurvedic and Unani medicine, Gloriosa superba (known as Kalihari or Langli) has been used for centuries to treat rheumatism, gout, snakebite, skin diseases, gonorrhea, and as an antifertility agent, with tuber decoctions and powders being the primary preparations. Regional herbalism in the Middle East and East Africa employed it for fever reduction, headache, and topical treatment of head lice. Despite historical use, all these applications were empirical and unsupported by controlled clinical evidence, and the inherent colchicine toxicity limited safe application.

Does Gloriosa superba have anticancer properties?

In vitro studies show that methanolic seed extracts of Gloriosa superba exhibit cytotoxicity against MDA-MB-231 human breast cancer cells at an IC₅₀ of 19.52 µg/mL in MTT assays, with 60–80% growth inhibition at 50 µg/mL — comparable in assay conditions to doxorubicin reference controls. This activity is attributed to colchicine-mediated microtubule depolymerization, which arrests cells at the G2/M mitotic checkpoint. However, no animal studies or human clinical trials have confirmed therapeutic anticancer efficacy, and the toxicity profile prevents direct clinical translation of the crude plant extract.

How does Gloriosa superba differ from pharmaceutical colchicine?

Pharmaceutical colchicine is a purified alkaloid extracted and isolated from Gloriosa superba (or Colchicum autumnale) using column chromatography and HPLC to achieve precise dosing at 0.5–1.2 mg per dose with defined bioavailability and pharmacokinetics. Crude plant material, by contrast, delivers variable colchicine concentrations alongside other alkaloids (gloriosine, colchicoside) and secondary metabolites, making accurate dosing impossible and significantly increasing the risk of toxicity. Pharmaceutical colchicine has an established evidence base for gout, familial Mediterranean fever, and pericarditis; the raw plant has no equivalent clinical validation.

What is the difference between Gloriosa superba extract and standardized colchicine supplements?

Gloriosa superba extracts contain colchicine alongside other alkaloids and plant compounds, whereas standardized colchicine supplements isolate and quantify colchicine to precise doses. Standardized supplements offer predictable dosing for pharmaceutical applications, while whole plant extracts may provide additional phytochemicals that could have synergistic or modulating effects. The extract form is generally considered less reliable for clinical use due to variable alkaloid concentrations across different plant parts and growing conditions.

Which parts of Gloriosa superba contain the highest colchicine concentration?

The tubers and seeds of Gloriosa superba contain the highest concentrations of colchicine, with seeds typically showing elevated levels compared to other plant tissues. The corm (underground stem) is the most commonly used traditional source, though alkaloid content varies based on growing season, harvest timing, and plant maturity. Leaves and flowers contain lower but still bioactive colchicine levels, which is why traditional preparations target specific plant parts.

What clinical evidence supports using Gloriosa superba for gout and inflammatory conditions?

The colchicine in Gloriosa superba is well-documented to inhibit NLRP3 inflammasome activation and neutrophil migration, the same mechanisms that make pharmaceutical colchicine effective for acute gout attacks. However, most clinical evidence supporting colchicine for gout comes from pharmaceutical-grade, standardized formulations rather than whole plant extracts of Gloriosa superba. Traditional use in Ayurvedic and African medicine supports anti-inflammatory applications, but high-quality clinical trials specifically testing Gloriosa superba preparations are limited.

Glory Lily

Gloriosa superba contains colchicine as its dominant alkaloid (2.12–7.58 mg/g in rhizomes, 7–9 mg/g in seeds), which binds β-tubulin to inhibit microtubule polymerization, blocking mitosis and neutrophil chemotaxis. In vitro, methanolic seed extracts demonstrated cytotoxicity against MDA-MB-231 breast cancer cells at an IC₅₀ of 19.52 µg/mL (MTT assay), and tuber extracts produced a 20 mm inhibition zone against MRSA, though no human clinical trials have been completed.

Category: Middle Eastern Evidence: 1/10 Tier: Preliminary

Origin & History

Gloriosa superba is native to tropical Africa and Asia, spanning sub-Saharan Africa through India, Sri Lanka, and Southeast Asia, thriving in well-drained sandy or loamy soils at altitudes up to 2,500 meters with warm, humid conditions. It has been cultivated across India, particularly in Andhra Pradesh, Tamil Nadu, and Gujarat, where systematic chemotyping of 32 wild populations has identified high-yield rhizome accessions producing up to 7.58 mg colchicine per gram dry weight. The plant grows as a climbing geophyte with prominent tuberous rhizomes, and commercial cultivation has intensified in South Asia and East Africa following pharmaceutical demand for its colchicine content.

Historical & Cultural Context

Gloriosa superba has been documented in Ayurvedic texts (Charaka Samhita, Sushruta Samhita) and Unani medicine for centuries under the Sanskrit name 'Langli' or 'Kalihari,' where it was prescribed for rheumatism, gout, skin diseases, wounds, snake bites, antifertility, and as an abortifacient — reflecting awareness of its potent biological activity. In West and East African traditional medicine, the tuber decoctions were used to treat sexually transmitted infections including gonorrhea, and the plant features prominently in ethnobotanical records of Kenya, Tanzania, and Zimbabwe as both a medicinal and poisoning agent. Middle Eastern regional herbalism adopted the plant through trade and migration routes from South Asia, incorporating it into preparations for fever, headache, and ectoparasite control, particularly head lice, using topical paste formulations. Gloriosa superba holds the distinction of being the national flower of Zimbabwe and a protected species in India under the Wildlife Protection Act (1972) due to over-harvesting pressures driven by pharmaceutical colchicine demand, reflecting its dual cultural and economic significance.

Health Benefits

- **Anti-inflammatory (Gout and Rheumatism)**: Colchicine inhibits neutrophil chemotaxis and NLRP3 inflammasome activation, reducing urate crystal-induced inflammation; this mechanism is well-established for pharmaceutical-grade colchicine derived from this plant.
- **Anticancer Activity**: Methanolic seed extracts showed IC₅₀ of 19.52 µg/mL against MDA-MB-231 breast cancer cells in MTT assays, with 60–80% cell growth inhibition at 50 µg/mL, attributed to colchicine-mediated mitotic arrest.
- **Antimicrobial Effects**: Tuber extracts demonstrated a 20 mm inhibition zone against MRSA in disc-diffusion assays; gloriosine and flavonoid fractions contribute additional bacteriostatic activity against Gram-positive and Gram-negative pathogens.
- **Antipyretic and Analgesic Action**: Traditional Ayurvedic and Unani use for fever and headache is supported by salicylic acid and flavonoid content, which modulate prostaglandin synthesis via COX pathway inhibition.
- **Antiparasitic and Ectoparasiticidal Use**: Regional herbalism in the Middle East and South Asia employs seed and tuber preparations topically against head lice; alkaloid and saponin fractions disrupt arthropod neural and membrane function.
- **Enzyme Inhibition for Neurological Research**: Isolated fractions demonstrated 83.50% inhibition of acetylcholinesterase, suggesting potential relevance to cholinergic signaling, though this has only been explored in vitro.
- **Antioxidant Activity**: Flavonoids, tannins, and saponins extracted from aerial parts and tubers exhibit free-radical scavenging capacity, with lipoxygenase inhibition reaching approximately 90% in enzymatic assays, supporting anti-inflammatory and cytoprotective roles.

How It Works

Colchicine, the primary alkaloid of Gloriosa superba, binds with high affinity to the colchicine-binding site on β-tubulin at the αβ-tubulin heterodimer interface, preventing GTP-dependent polymerization of tubulin into microtubules and thereby arresting dividing cells at the G2/M phase of the cell cycle; at low doses this suppresses neutrophil migration by disrupting cytoskeletal dynamics, while at higher doses it induces chromosomal non-disjunction and apoptosis in rapidly proliferating cells. Gloriosine, a structural analog of colchicine, shares tubulin-binding properties and contributes synergistically to mitotic inhibition and induction of polyploidy used in plant breeding programs. Flavonoids and saponins in the extracts exert secondary mechanisms including inhibition of 5-lipoxygenase (approximately 90% enzymatic inhibition), acetylcholinesterase suppression (83.50%), and direct membrane disruption in microbial and parasitic targets. Colchicoside, the glycoside form, undergoes hydrolysis to release colchicine in physiological conditions, extending the duration of microtubule-disrupting activity while modulating the pharmacokinetic profile of total alkaloid absorption.

Scientific Research

The evidence base for Gloriosa superba consists entirely of in vitro and phytochemical studies; no randomized controlled trials or human clinical studies have been published as of the available literature. Preclinical anticancer data include MTT-based cytotoxicity assays against MDA-MB-231 cells (IC₅₀ 19.52 µg/mL for methanolic seed extract) and antimicrobial disc-diffusion assays reporting a 20 mm inhibition zone against MRSA, but these represent preliminary screening data without pharmacokinetic, dose-escalation, or efficacy confirmation in animal or human models. Chemotypic characterization studies across 32 Indian populations have rigorously quantified colchicine content (2.12–7.58 mg/g in tubers; up to 9 mg/g in seeds) using TLC, HPLC, GC-MS, and FTIR, providing robust phytochemical standardization data relevant to pharmaceutical extraction but not to clinical supplementation. The traditional use in Ayurveda and Unani medicine for gonorrhea, rheumatism, antifertility, and ectoparasitic infestation lacks controlled human evidence, and the narrow therapeutic index of colchicine renders translational clinical research ethically constrained without careful dose formulation.

Clinical Summary

No human randomized controlled trials have been conducted specifically using Gloriosa superba extracts as a therapeutic agent; the entire clinical evidence base is extrapolated from pharmaceutical-grade isolated colchicine trials (e.g., for gout and familial Mediterranean fever) that confirm the mechanism operative in this plant. In vitro studies using the plant's methanolic extracts show cytotoxic activity at IC₅₀ values in the range of 19.52 µg/mL against breast cancer lines, but these concentrations are far below those achievable safely in vivo without systemic toxicity. Enzyme inhibition assays (lipoxygenase 90%, acetylcholinesterase 83.50%) provide mechanistic plausibility for anti-inflammatory and neurological applications, yet no dose-response, bioavailability, or tolerability data exist for human consumption. Confidence in clinical outcomes for the raw plant material is very low; safety concerns from colchicine's narrow therapeutic index (toxic dose closely approximates therapeutic dose) make human trials with unfractionated extracts unlikely without pharmaceutical-grade purification and dosing control.

Nutritional Profile

Gloriosa superba is not a nutritional food source and is not consumed for macronutrient content; it is exclusively a medicinal and pharmaceutical plant. The tubers and seeds are dominated by alkaloids (colchicine 2.12–7.58 mg/g in rhizomes; 7–9 mg/g in seeds), with colchicoside and gloriosine contributing additional alkaloid mass. Secondary metabolites identified include flavonoids, saponins, tannins, sterols (including β-sitosterol), salicylic acid, benzoic acid, and free fatty acids; GC-MS analysis identified 9 compounds in tubers and 17 in seeds, including α-lumicolchicine and superbine. Bioavailability of colchicine from plant material is high due to its lipophilic nature, with rapid gastrointestinal absorption and hepatic metabolism via CYP3A4 and P-glycoprotein efflux, contributing to its narrow therapeutic-to-toxic ratio. No meaningful dietary vitamins, minerals, or macronutrients have been characterized in edible concentrations.

Preparation & Dosage

- **Traditional Tuber Decoction**: Rhizomes were historically dried, powdered, and decocted in small quantities in Ayurvedic practice for rheumatism and antifertility; exact doses were not standardized and this approach carries high toxicity risk.
- **Seed Powder**: Seeds contain the highest colchicine concentration (7–9 mg/g dry weight) and were used in traditional preparations for gout and inflammatory conditions, but no safe oral dose from crude seed material has been established.
- **Topical Paste (Ectoparasitic Use)**: Tuber paste applied to the scalp for head lice treatment in regional herbalism; concentration and application frequency were empirical and unstandardized.
- **Pharmaceutical Colchicine Extraction**: Industrial extraction via column chromatography and HPLC purification from rhizomes or seeds yields pharmaceutical-grade colchicine; standard medical dosing for gout is 0.5–1.2 mg per dose (not from crude plant material).
- **NOT RECOMMENDED as a Dietary Supplement**: No safe or standardized supplemental form of Gloriosa superba extract exists; the colchicine content at even low extract doses can exceed the narrow therapeutic threshold and cause life-threatening toxicity.
- **Research/Extraction Context Only**: GC-MS and TLC-guided fractionation is used for phytochemical research and pharmaceutical-grade colchicine production, not for consumer supplementation.

Synergy & Pairings

No evidence-based synergistic supplement stacks have been established for Gloriosa superba given its toxicity profile and absence of human trials; historically, Ayurvedic formulations combined small quantities of Langli (G. superba) tuber with black pepper (Piper nigrum) to enhance bioavailability of alkaloids via piperine-mediated CYP3A4 modulation, though this combination also increases colchicine absorption and toxicity risk. In pharmaceutical research contexts, colchicine isolated from G. superba has been studied in combination with probenecid (a uricosuric agent) for gout management, where the combination addresses both uric acid overproduction and neutrophil-mediated inflammation through complementary mechanisms. Any synergistic combination involving G. superba plant material amplifies toxicity risk proportionally and should be regarded as hazardous outside of controlled pharmaceutical formulation.

Safety & Interactions

Gloriosa superba is among the most toxic plants encountered in clinical toxicology; colchicine poisoning from ingestion of tubers or seeds presents as a multistage syndrome including severe gastrointestinal distress (vomiting, diarrhea, abdominal pain) within 2–6 hours, followed by multi-organ failure (cardiac arrhythmia, renal failure, hepatotoxicity, bone marrow suppression, and neuromuscular paralysis) within 24–72 hours, with a reported case-fatality rate in unintentional poisoning events. Colchicine interacts dangerously with CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, ritonavir), P-glycoprotein inhibitors (e.g., cyclosporine, verapamil), and other cytotoxic agents, resulting in elevated plasma colchicine concentrations that can precipitate life-threatening toxicity even at doses considered therapeutic for pharmaceutical colchicine. The plant is absolutely contraindicated in pregnancy (documented abortifacient and teratogenic effects via mitotic disruption), during lactation, and in individuals with renal or hepatic impairment due to reduced clearance and dramatically narrowed therapeutic index. No safe supplemental dose of crude Gloriosa superba extract has been established; all traditional and modern uses carry significant risk, and self-medication with any plant part is strongly discouraged — accidental poisoning incidents are regularly reported in South Asia and Africa.